Diabetes in pregnancy, whether pregestational type 1 or type 2 diabetes, or gestational diabetes mellitus (GDM), is one of the most common and high-risk medical conditions encountered in obstetric care. Poorly controlled glucose during pregnancy has been consistently associated with adverse outcomes for both mothers and their babies. Fortunately, advances in technology—specifically continuous glucose monitoring (CGM)—offer powerful tools to help women achieve tighter glucose control and reduce complications.
This article reviews the importance of glucose management during pregnancy, the risks of uncontrolled diabetes, and the role of CGM in improving outcomes, drawing from key landmark studies.
The Impact of Poor Glucose Control in Pregnancy
Pregnancy places unique metabolic demands on the body. As hormones shift to support fetal growth, insulin resistance increases, often requiring women with preexisting diabetes to substantially adjust their therapy. Even women without prior diabetes may develop GDM due to these physiologic changes.
The Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) Study, a pivotal multicenter investigation involving over 25,000 pregnant women, demonstrated a strong, continuous relationship between maternal hyperglycemia and adverse outcomes, even below the thresholds used to diagnose diabetes (HAPO Study Cooperative Research Group, 2008).¹ Specifically, the study linked elevated maternal glucose to:
- Macrosomia (large for gestational age infants) – Increasing risk of birth trauma and cesarean delivery.
- Neonatal hypoglycemia – Low blood sugar after birth requiring intervention.
- Pre-eclampsia – Elevated maternal blood pressure with serious risks for both mother and baby.
- Increased neonatal adiposity – Higher long-term risk for obesity and metabolic disease.
The HAPO findings reshaped global guidelines, underscoring that even mild elevations in glucose levels can lead to clinically meaningful complications. For these reasons, close monitoring and effective control of maternal glucose are critical throughout pregnancy.
Epigenetics and Long-Term Impact of Elevated Glucose in Pregnancy
The emerging field of epigenetics—the study of how environmental factors can alter gene expression without changing the DNA sequence—is providing new insights into how maternal hyperglycemia affects long-term health. Evidence suggests that exposure to high glucose levels in utero can trigger epigenetic modifications, such as DNA methylation and changes in histone structure, which may influence how genes related to metabolism, growth, and insulin sensitivity are expressed. These changes do not cause genetic mutations but can “program” the developing fetus toward an increased risk of obesity, type 2 diabetes, and cardiovascular disease later in life. This growing body of research underscores the importance of maintaining tight glucose control during pregnancy, not only for immediate perinatal outcomes but also for shaping the lifelong health trajectory of the child.
Traditional Glucose Monitoring: Limitations
For decades, the standard approach to monitoring glucose in pregnancy has been self-monitoring of blood glucose (SMBG) using finger-stick tests several times per day. While effective to some degree, SMBG provides only snapshots of glucose levels at discrete points in time. Important fluctuations—such as nocturnal hypoglycemia or post-meal spikes—can be missed.
Moreover, pregnancy demands particularly stringent glycemic targets:
- Fasting glucose: <95 mg/dL
- 1-hour postprandial: <140 mg/dL
- 2-hour postprandial: <120 mg/dL
Achieving these values requires continuous awareness and rapid therapeutic adjustments, which are difficult with intermittent finger-stick testing alone. Patients also face the burden of frequent testing, which can reduce adherence.
The Role of Continuous Glucose Monitoring (CGM)
Continuous glucose monitoring (CGM) represents a transformative advance in diabetes care. CGM systems measure interstitial glucose levels every 1–5 minutes via a small sensor placed under the skin. Results are displayed in real time on a receiver or smartphone app, with trend arrows and alerts for highs and lows.
This technology allows pregnant patients and their care teams to see:
- Daily glucose trends rather than isolated numbers.
- Post-meal excursions that finger-sticks may miss.
- Nocturnal glucose patterns, identifying unrecognized hypoglycemia.
- Time-in-range (TIR) metrics, a key measure reflecting the percentage of time glucose levels stay within target zones.
CGM empowers women with actionable insights—when to adjust meals, physical activity, or insulin dosing—while also enabling clinicians to optimize therapy during pregnancy.
Evidence for CGM in Pregnancy
Early Studies
Gonzalez-Quintero and colleagues (2007) evaluated CGM in women with gestational diabetes and found that short-term use of CGM detected postprandial hyperglycemia and nocturnal hypoglycemia that were missed by SMBG.² Importantly, these insights led to therapy adjustments that improved maternal glycemic control.
The CONCEPTT Trial
The most influential trial supporting CGM in pregnancy is the CONCEPTT study (Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy), led by Feig and colleagues (2017).³ This randomized controlled trial involved over 300 women with type 1 diabetes, comparing CGM plus SMBG versus SMBG alone.
Key findings included:
- Improved maternal outcomes: CGM users had lower HbA1c levels and spent more time in target glucose ranges.
- Better neonatal outcomes: Babies born to mothers using CGM had significantly lower rates of large-for-gestational-age birth, neonatal intensive care unit (NICU) admission longer than 24 hours, and neonatal hypoglycemia.
- Greater safety: No increase in maternal severe hypoglycemia was observed, addressing a key safety concern in intensive glucose control.
The CONCEPTT trial firmly established CGM as not only a tool for better glucose numbers but also as an intervention that leads to real, measurable improvements in maternal and infant health.
Benefits of CGM in Clinical Practice
- Better Glucose Control
Real-time feedback allows for prompt correction of highs and lows, helping women meet the stringent pregnancy targets more consistently. - Reduced Complications
By lowering the risk of macrosomia, neonatal hypoglycemia, and NICU admissions, CGM improves both short- and long-term outcomes for infants. - Patient Empowerment
Many women report greater confidence and peace of mind when using CGM, especially with alarm features that warn of impending hypo- or hyperglycemia. - Data-Driven Care
Clinicians gain access to detailed glucose reports—such as Ambulatory Glucose Profiles (AGP)—which inform more precise insulin or diet adjustments.
Challenges and Considerations
Despite strong evidence, some barriers remain in widespread CGM adoption during pregnancy:
- Cost and insurance coverage: While coverage is improving, CGM remains expensive for many patients.
- Technology comfort: Some women may be hesitant to use wearable devices or may find sensor insertion uncomfortable.
- Data overload: Interpreting the wealth of data from CGM requires patient education and provider expertise.
Nevertheless, ongoing advocacy and guideline updates continue to expand access, and many clinicians now view CGM as a standard component of diabetes care in pregnancy.
Looking Ahead
Research continues to refine the role of CGM in pregnancy, with newer studies evaluating its use in gestational diabetes and type 2 diabetes, as well as its integration with automated insulin delivery (AID) systems. Early results suggest that combining CGM with insulin pumps may further optimize control while reducing patient burden.
As technology becomes more user-friendly and accessible, it is likely that CGM will become a routine part of prenatal care for women with diabetes, similar to how ultrasound is universally employed today.
Conclusion
Poor glucose control in pregnancy is not just a laboratory number—it translates directly into higher risks of pre-eclampsia, cesarean birth, NICU admission, and long-term health problems for both mother and child. The HAPO study firmly established these risks, and subsequent research has shown that traditional monitoring often falls short in helping women achieve optimal control.
Continuous glucose monitoring bridges this gap. By providing real-time, comprehensive glucose data, CGM empowers women to maintain tighter control and enables clinicians to fine-tune therapy. The CONCEPTT trial and related studies provide robust evidence that CGM not only improves glucose numbers but also reduces serious complications for newborns.
In the era of precision medicine, CGM represents a clear step forward in ensuring safer pregnancies and healthier futures for mothers and their babies.
References
- HAPO Study Cooperative Research Group, et al. Hyperglycemia and Adverse Pregnancy Outcomes. N Engl J Med. 2008;358(19):1991-2002.
- Gonzalez-Quintero VH, et al. The impact of glycemic control on pregnancy outcomes in women with gestational diabetes. Diabetes Care. 2007;30(3):467-470.
- Feig DS, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomized controlled trial. Lancet. 2017;390(10110):2347-2359.
El Camino Women’s Medical Group offers the latest Minimally Invasive Solutions for gynecologic problems. Drs. Amy Teng, Erika Balassiano, Pooja Gupta, and Vivian Wan, all members of AAGL (American Association of Gynecologic Laparoscopy), are highly trained and experienced in the field of Minimally Invasive Gynecologic Surgery. Dr. Erika Balassiano has also completed a Minimally Invasive Gynecologic Surgery Fellowship under the supervision of world-renowned Dr. Camran Nezhat. Angel Wong, PA-C, is a physician assistant who sees patients for routine and lower-acuity care.
All of our physicians are El Camino Hospital doctors and operate and deliver at the Mountain View campus.
As part of El Camino Women’s Medical Group’s commitment to comprehensive care for women, we offer in-network mental health services with world-renowned psychiatrist Dr. Rania Awaad and experienced therapist Daniya Ahmed, LMFT. For women seeking to improve their health through a healthier diet, Mariam AlAgha, MS, is an excellent nutritionist with over a decade of success helping women achieve their health goals. Her services are also in network.
Serving Mountain View, Los Altos, Los Altos Hills, Atherton, Palo Alto, Redwood City, Burlingame, Saratoga, Cupertino, Sunnyvale, Los Gatos, Campbell, San Jose, Santa Clara, Silicon Valley, Milpitas, Fremont, South Bay, East Bay, and North Bay.